Chronos' Deal With Shire Is 'Just The Start' Of Its Acquisitive New Strategy

Chronos Therapeutics' acquisition of three preclinical central nervous system (CNS) disease-targeting assets from Shire PLC is the first of a possible series of deals the emerging biotech is seeking under its new business strategy.